There are press releases popping out on JDRF’s CGM Study and Biodel phase III out today.
JDRF found significant benifits with CGM.
Biodel is reporting preliminary phase III non-inferiority.
I’ll link more at YDMV as I hear it.
Please go to this discussion (http://tudiabetes.com/forum/topic/show?id=583967%3ATopic%3A248568) for a link to the full JDRF article. Again, sorry for splitting the discussion, but I couldn’t get the file to attach here.